Ubix Therapeutics
PrivateLast Round
Growth Equity
Dec 23, 2024
Total Funding Raised
$46.3M
Company Overview
Ubix Therapeutics is a biotechnology company that develops novel anti-cancer therapies using its proprietary targeted protein degradation platform, Degraducer®.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ubix Therapeutics Comparables
Compare Ubix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prazer Therapeutics | 89% | |
| Cyrus Therapeutics | 88% | |
| Pin Therapeutics | 88% | |
Ubix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Dec 23, 2024 | ||||
| Series C | Jul 1, 2023 | ||||
| Series B | May 6, 2020 | ||||
| Series A | Feb 1, 2019 |
Ubix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KOTEC | Growth Equity |
| BNH INVESTMENT | Series C |
| UTC Investment | Series B, Series C |
| Premier Partners | Series B, Series A |
| QUAD Investment Management | Growth Equity |
| GeneN Investment Partners | Series C |
| Medytox Venture Investment | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors increased 42% MoM to 4.8K.
- Jun 1, 2025
Monthly visitors increased 88% MoM, reaching 3K.
Ubix Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ubix Therapeutics's valuation, stock price, and market status.